BMS-986278 succeeds in phase 2 idiopathic pulmonary fibrosis trial, says Bristol Myers Squibb
Bristol Myers Squibb (BMS) said that BMS-986278 has succeeded in lowering the rate of lung function decline in idiopathic pulmonary fibrosis patients in a phase ... Read More
BMS, bluebird bio bag Abecma FDA approval for multiple myeloma in adults
Abecma FDA approval : Bristol Myers Squibb (BMS) and bluebird bio have secured approval from the US Food and Drug Administration (FDA) for Abecma (idecabtagene ... Read More
Novartis’ Kisqali plus endocrine therapy shows significant PFS benefits in advanced breast cancer trials
Swiss pharmaceutical giant Novartis has announced that its breast cancer drug, Kisqali (ribociclib), when used in combination with endocrine therapy, has demonstrated substantial efficacy in ... Read More